Drugs Made In America Acquisition II Corp. SEC filings DMIIR

Drugs Made In America Acquisition II Corp. has 45 filings in SEC EDGAR's recent list, going back to Mar 19, 2025. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Apr 28, 2026 (material agreement). The company's fiscal year ends on December 31.

Drugs Made In America Acquisition II Corp. SEC filings
Form Description Filed Period
NT 10-K Notification of late filing Apr 1, 2026 Dec 31, 2025
NT 10-Q Notification of late filing Nov 17, 2025 Sep 30, 2025
EFFECT Filing Sep 24, 2025 —
CERT Filing Sep 24, 2025 —
8-A12B For registration of certain classes Sep 24, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
CORRESP Letter to the SEC Sep 16, 2025 —
UPLOAD Letter from the SEC Sep 15, 2025 —
CORRESP Letter to the SEC Jul 18, 2025 —
UPLOAD Letter from the SEC May 2, 2025 —
DRSLTR Filing Apr 25, 2025 —
DRS/A Filing Apr 25, 2025 —
UPLOAD Letter from the SEC Apr 14, 2025 —
DRS Filing Mar 19, 2025 —

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Blank Checks (SIC 6770)
Listed as
DMII (Nasdaq), DMIIR (Nasdaq), DMIIU (Nasdaq)
Fiscal year ends
December 31
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2040475

Other Blank Checks companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.